Skip to main content
SpringerLink
Log in

Neues zur Pathogenese der Psoriasisarthritis

New aspects on the pathogenesis of psoriatic arthritis

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Psoriasis und Psoriasisarthritis (PsA) sind chronisch entzündliche immunvermittelte Erkrankungen mit erheblicher Funktionseinschränkung und erhöhter Mortalität. Pathophysiologisch zeigt sich eine Störung im Zusammenspiel zwischen Gewebe- und Immunzellen als auch des Zytokinnetzwerks und somit eine chronische Entzündung der Haut, Enthesen und Gelenke. Das Verständnis von immunologischen Vorgängen und einiger Schlüsselmoleküle wie TNF-α, IL-12/IL-23 und der IL-17-Achse bilden die Grundlage für mögliche, Erfolg versprechende antirheumatische Therapien. Dieser kurze Überblick soll auch anhand neuer, sich in Studien befindender Zielmoleküle einen Einblick in das Verständnis der Pathogenese der PsA geben.

Abstract

Psoriasis and psoriatic arthritis (PsA) are immune-mediated inflammatory diseases with a high burden of disability and increased mortality. The pathogenesis of the disease comprises a dysregulated interaction between stromal and immune cells and a dysfunctional cytokine network supporting chronic inflammation of the skin, entheses and joints. In addition to recent advances in the understanding of TNF blockade, more targets have been discovered delivering insights into the pathogenesis of PsA. This article gives a translational approach by utilizing current clinical development programs providing an insight into the IL-12/IL-23 and the IL-17 axes and also focuses on tissue damage and new small molecules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Atzeni F, Ventura D, Batticciotto A et al (2012) Interleukin 6 blockade: tocilizumab in psoriatic arthritis. J Rheumatol Suppl 89:97–99

    Article  PubMed  CAS  Google Scholar 

  2. Braem K, Carter S, Lories RJ (2012) Spontaneous arthritis and ankylosis in male DBA/1 mice: further evidence for a role of behavioral factors in „stress-induced arthritis“. Biol Proced Online 14:10

    Article  PubMed  Google Scholar 

  3. Celis R, Planell N, Fernandez-Sueiro JL et al (2012) Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 14:R93

    Article  PubMed  CAS  Google Scholar 

  4. Ema (2013) Refusal of the marketing authorisation for Xeljanz (tofacitinib). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002542/WC500142485.pdf EMA/248755/2013

  5. Frey S, Derer A, Messbacher ME et al (2013) The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 72:1569–1574

    Article  PubMed  CAS  Google Scholar 

  6. Gottlieb A, Menter A, Mendelsohn A et al (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373:633–640

    Article  PubMed  CAS  Google Scholar 

  7. Hueber AJ, Alves-Filho JC, Asquith DL et al (2011) IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 41:2229–2237

    Article  PubMed  CAS  Google Scholar 

  8. Hueber AJ, Asquith DL, Miller AM et al (2010) Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184:3336–3340

    Article  PubMed  CAS  Google Scholar 

  9. Lamacchia C, Palmer G, Rodriguez E et al (2013) The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Res Ther 15:R38

    Article  PubMed  CAS  Google Scholar 

  10. Leipe J, Grunke M, Dechant C et al (2010) Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62:2876–2885

    Article  PubMed  CAS  Google Scholar 

  11. Lories RJ, Derese I, Luyten FP (2005) Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 115:1571–1579

    Article  PubMed  CAS  Google Scholar 

  12. McGonagle D, Benjamin M, Tan AL (2009) The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol 21:340–347

    Article  PubMed  CAS  Google Scholar 

  13. McInnes IB, Sieper J, Braun J et al (2013) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis (Online veröffentlicht vor Drucklegung)

  14. Mease PJ (2012) Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis? J Rheumatol 39:2235–2237

    Article  PubMed  CAS  Google Scholar 

  15. Millar NL, Murrell GA, Mcinnes IB (2013) Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatology 52:769–779

    Article  PubMed  CAS  Google Scholar 

  16. Patel DD, Lee DM, Kolbinger F et al (2013) Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 72(Suppl 2):ii116–ii123

    Article  PubMed  CAS  Google Scholar 

  17. Pattison E, Harrison BJ, Griffiths CE et al (2008) Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 67:672–676

    Article  PubMed  CAS  Google Scholar 

  18. Ritchlin CT, Haas-Smith SA, Li P et al (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821–831

    PubMed  CAS  Google Scholar 

  19. Schafer P (2012) Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 83:1583–1590

    Article  PubMed  CAS  Google Scholar 

  20. Theoharides TC, Zhang B, Kempuraj D et al (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A 107:4448–4453

    Article  PubMed  CAS  Google Scholar 

  21. Yazici Y, Steiger B (2012) Kinase inhibitors for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 70:204–207

    PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. A. Hueber erhielt Vortragshonorare von Roche/Chugai, Bristol-Myers Squibb, Pfizer, Abbott und Mundipharma. B. Manger erhielt Honorare für Vortrags- und Beratungstätigkeiten von Abbott, BMS, Janssen, MSD, Novartis, Pfizer, Roche/Chugai, UCB. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Medizinische Klinik 3, Rheumatologie und Immunologie, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland

    A.J. Hueber & B. Manger

Authors
  1. A.J. Hueber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Manger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A.J. Hueber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hueber, A., Manger, B. Neues zur Pathogenese der Psoriasisarthritis. Z. Rheumatol. 72, 758–763 (2013). https://doi.org/10.1007/s00393-013-1186-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-013-1186-x

Schlüsselwörter

Keywords

Search

Navigation